


Abstract


The present invention relates to compounds of the Formula I, the pharmaceutically acceptable salts and stereoisomers thereof, which inhibit, regulate and/or modulate tyrosine kinase signal transduction, compositions
 5 which contain these compounds, and methods of using them to treat tyrosine kinase-dependent diseases and conditions in mammals:

Formula I

wherein n is an integer, preferably n is 1;

wherein R₁ and R₂ are independently selected from the group consisting

10 of:



(19) World Intellectual Property
Organization
International Bureau



(43) International Publication Date
5 February 2004 (05.02.2004)

PCT

(10) International Publication Number
WO 2004/011456 A1

(51) International Patent Classification⁷: C07D 401/14,
A61K 31/506, A61P 35/00

(74) Agent: MCMANUS, Kimberly, A.,; Sim & McBurney,
330 University Avenue, Sixth Floor, Toronto, Ontario M5G
1R7 (CA).

(21) International Application Number:
PCT/CA2003/001162

(22) International Filing Date: 31 July 2003 (31.07.2003)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
60/399,408 31 July 2002 (31.07.2002) US

(71) Applicant and
(72) Inventor: DANTER, Wayne, R., [CA/CA]; 147 Chesham
Avenue, London, Ontario N6G 3V2 (CA).

(81) Designated States (*national*): AE, AG, AL, AM, AT, AU,
AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU,
CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH,
GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC,
LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW,
MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC,
SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA,
UG, US, UZ, VC, VN, YU, ZA, ZM, ZW.

(84) Designated States (*regional*): ARIPO patent (GH, GM,
KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW),
Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM),
European patent (AT, BE, BG, CH, CY, CZ, DE, DK, EE,
ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO,
SE, SI, SK, TR), OAPI patent (BF, BJ, CF, CG, CI, CM,
GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

(71) Applicants and
(72) Inventors (*for US only*): BROWN, Martyn [GB/CA]; 349
Wildcat Road, Toronto, Ontario M3J 2S3, Canada (CA).
MA, George [GB/CA]; 349 Wildcat Road, Toronto, On-
tario M3J 2S3 (CA).


Published:

- with international search report
- before the expiration of the time limit for amending the
claims and to be republished in the event of receipt of
amendments

(71) Applicants and
(72) Inventors (*for US only*): RUSU, Ghenadie [MD/CA];
349 Wildcat Road, Toronto, Ontario M3J 2S3 (CA).
ZHONG, Jianhua [CA/CA]; 349 Wildcat Road, Toronto,
Ontario M3J 2S3, Canada (CA). LAZAROWYCH,
Natalie [CA/CA]; 349 Wildcat Road, Toronto, Ontario
M3J 2S3 (CA). HOULDSWORTH, Stephen [GB/CA];
349 Wildcat Road, Toronto, Ontario M3J 2S3 (CA).

For two-letter codes and other abbreviations, refer to the "Guid-
ance Notes on Codes and Abbreviations" appearing at the begin-
ning of each regular issue of the PCT Gazette.

(54) Title: PROTEIN TYROSINE KINASE INHIBITORS



(57) Abstract: The present invention relates to
compounds of the Formula I, the pharmaceutically
acceptable salts and stereoisomers thereof,
which inhibit, regulate and/or modulate tyrosine
kinase signal transduction, compositions which
contain these compounds, and methods of using
them to treat tyrosine kinase-dependent diseases
and conditions in mammals: wherein n is an
integer, preferably n is 1; wherein R₁ and R₂ are
independently selected from the group consisting of
H; alkyl; alkenyl; alkynyl; halogen; aryl; heteroaryl containing N, O, or S; the aryl and heteroaryl may be further substituted with
halogen, an alkyl, alkenyl, and alkynyl; NZ₁Z₂, wherein Z₁ and Z₂ are independently selected from the group consisting of H and
alkyl; and (CO)Y wherein Y is selected from the group consisting of H, alkyl, alkenyl, and alkynyl; and wherein R₄ is selected
from the group consisting of H and alkyl.

WO 2004/011456 A1